KZIA PE Ratio & Valuation,Is KZIA Overvalued

KZIA Relative Valuation

KZIA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, KZIA is overvalued; if below, it's undervalued.

Historical Valuation

Kazia Therapeutics Ltd (KZIA) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -91.82. The fair price of Kazia Therapeutics Ltd (KZIA) is between -- to -- according to relative valuation methord.

Relative Value

Fair Zone

-----

Current Price：9.51

Fair

-1226.19

0.00

EV/EBITDA

Kazia Therapeutics Ltd. (KZIA) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is -2.45. The thresholds are as follows: Strongly Undervalued below -11.37, Undervalued between -11.37 and -6.91, Fairly Valued between 2.01 and -6.91, Overvalued between 2.01 and 6.47, and Strongly Overvalued above 6.47. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.

-1.08

EV/EBIT

Kazia Therapeutics Ltd. (KZIA) has a current EV/EBIT of -1.08. The 5-year average EV/EBIT is -1.36. The thresholds are as follows: Strongly Undervalued below -12.50, Undervalued between -12.50 and -6.93, Fairly Valued between 4.22 and -6.93, Overvalued between 4.22 and 9.79, and Strongly Overvalued above 9.79. The current Forward EV/EBIT of -1.08 falls within the Historic Trend Line -Fairly Valued range.

587.13

Kazia Therapeutics Ltd. (KZIA) has a current PS of 587.13. The 5-year average PS is 305.59. The thresholds are as follows: Strongly Undervalued below -1703.40, Undervalued between -1703.40 and -698.90, Fairly Valued between 1310.09 and -698.90, Overvalued between 1310.09 and 2314.59, and Strongly Overvalued above 2314.59. The current Forward PS of 587.13 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/OCF

Kazia Therapeutics Ltd. (KZIA) has a current P/OCF of 0.00. The 5-year average P/OCF is -45.67. The thresholds are as follows: Strongly Undervalued below -420.05, Undervalued between -420.05 and -232.86, Fairly Valued between 141.53 and -232.86, Overvalued between 141.53 and 328.72, and Strongly Overvalued above 328.72. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

-0.71

P/FCF

Kazia Therapeutics Ltd. (KZIA) has a current P/FCF of -0.71. The 5-year average P/FCF is -45.73. The thresholds are as follows: Strongly Undervalued below -420.23, Undervalued between -420.23 and -232.98, Fairly Valued between 141.51 and -232.98, Overvalued between 141.51 and 328.76, and Strongly Overvalued above 328.76. The current Forward P/FCF of -0.71 falls within the Historic Trend Line -Fairly Valued range.

Kazia Therapeutics Ltd (KZIA) has a current Price-to-Book (P/B) ratio of -2.81. Compared to its 3-year average P/B ratio of 1.22 , the current P/B ratio is approximately -331.22% higher. Relative to its 5-year average P/B ratio of 2.65, the current P/B ratio is about -206.02% higher. Kazia Therapeutics Ltd (KZIA) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -81.82%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -59.37% , the current FCF yield is about -100.00% lower.

-2.81

P/B

Median3y

1.22

Median5y

2.65

-46.15

FCF Yield

Median3y

-81.82

Median5y

-59.37

Competitors Valuation Multiple

The average P/S ratio for KZIA's competitors is 0.00, providing a benchmark for relative valuation. Kazia Therapeutics Ltd Corp (KZIA) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of KZIA increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of KZIA in the past 1 year is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is Kazia Therapeutics Ltd (KZIA) currently overvalued or undervalued?

What is Kazia Therapeutics Ltd (KZIA) fair value?

KZIA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Kazia Therapeutics Ltd (KZIA) is between to according to relative valuation methord.

How does KZIA's valuation metrics compare to the industry average?

What is the current P/B ratio for Kazia Therapeutics Ltd (KZIA) as of Dec 16 2025?

As of Dec 16 2025, Kazia Therapeutics Ltd (KZIA) has a P/B ratio of -2.81. This indicates that the market values KZIA at -2.81 times its book value.

What is the current FCF Yield for Kazia Therapeutics Ltd (KZIA) as of Dec 16 2025?

As of Dec 16 2025, Kazia Therapeutics Ltd (KZIA) has a FCF Yield of 0.00%. This means that for every dollar of Kazia Therapeutics Ltd’s market capitalization, the company generates 0.00 cents in free cash flow.

What is the current Forward P/E ratio for Kazia Therapeutics Ltd (KZIA) as of Dec 16 2025?

As of Dec 16 2025, Kazia Therapeutics Ltd (KZIA) has a Forward P/E ratio of -1226.19. This means the market is willing to pay $-1226.19 for every dollar of Kazia Therapeutics Ltd’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Kazia Therapeutics Ltd (KZIA) as of Dec 16 2025?

As of Dec 16 2025, Kazia Therapeutics Ltd (KZIA) has a Forward P/S ratio of 0.00. This means the market is valuing KZIA at $0.00 for every dollar of expected revenue over the next 12 months.

KZIA Valuation